Ibandronate in metastatic bone pain

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 67-72

  Heidenreich, Axel ^a   Ohlmann, Carsten ^b   Body, Jean Jacques ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; OPIATE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DISEASE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; HEALTH CARE; HUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; URINARY TRACT CANCER;

ADMINISTRATION, ORAL; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; HUMANS; INFUSIONS, INTRAVENOUS; PAIN; UROLOGIC NEOPLASMS;

EID: 5644304284     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.026     Document Type: Conference Paper

References (40)

1. J.J. Bonica Management of cancer pain Acta Anaesthesiol Scand Suppl 74 suppl 1982 75 82
2. C.S.B. Galasko Skeletal Metastases 1986 Butterworth London
3. E.F. Solomayer, I.J. Diel, G.C. Meyberg Metastatic breast cancer clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Res Treat 59 2000 271 278
4. A.N. Serafini Therapy of metastatic bone pain J Nucl Med 42 2001 895 906
5. N. Janjan Bone metastases approaches to management Semin Oncol 28 suppl 11 2001 28 34
6. S. Mercadante Malignant bone pain pathophysiology and treatment Pain 69 1997 1 18
7. World Health Organization Cancer pain relief and palliative care report of a WHO expert committee 1990 World Health Organization Geneva, Switzerland
8. J.J. Body, R. Bartl, P. Burckhardt International Bone and Cancer Study Group Current use of bisphosphonates in oncology J Clin Oncol 16 1998 3890 3899
9. L.S. Rosen, D. Gordon, M. Kaminski Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma a phase III, double blind, comparative trial Cancer J 7 2001 377 387
10. Pavlakis N, Stockler M Bisphosphonates for breast cancer. Cochrane Database Syst Rev 1 2002 CD003474
11. F. Saad, D.M. Gleason, R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
12. J.J. Body, I.J. Diel, M.R. Lichinitser Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
13. J.J. Body, I.J. Diel, M. Lichinitzer Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
14. J.R. Berenson, A. Lichtenstein, L. Porter Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma N Engl J Med 334 1996 488 493
15. P.F. Conte, J. Latreille, L. Mauriac Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate results from a multinational randomized controlled trial J Clin Oncol 14 1996 2552 2559
16. D.S. Ernst, R.N. MacDonald, A.H. Paterson A double-blind, crossover trial of intravenous clodronate in metastatic bone pain J Pain Symptom Manage 7 1992 4 11
17. Heidenreich A, Hofmann R, Engelmann UH The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165 2001 136 140
18. J.J. Vinholes, O.P. Purohit, M.E. Abbey Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease Ann Oncol 8 1997 1243 1250
19. I.J. Diel, J.-J. Body, M.R. Lichinitser Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer Eur J Cancer 401 2004 1704 1712
20. R.E. Coleman Assessment of response to treatment R.D. Rubens I. Forgelman Bone Metastases Diagnosis and Treatment 1991 Springer Berlin 99 120
21. N.K. Aaronson, S. Ahmedzai, B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30 a quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 375
22. I. Mancini, J.-C. Dumon, J.-J. Body Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease a pilot study J Clin Oncol 22 2004 3587 3592
23. E. Bruera, M. Michaud, A. Vigano Multidisciplinary symptom control clinic in a cancer center a retrospective study Support Care Cancer 9 2001 162 168
24. A. Jacox, D.B. Carr, R. Payne Management of cancer pain. Quick reference guide for clinicians. Clinical Practice Guideline No. 9 1994 Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service Rockville, MD AHCPR Publication No. 94-0592, March
25. E. Bruera, T. Schoeller, R. Wenk A prospective multicenter assessment of the Edmonton staging system for cancer pain J Pain Symptom Manage 10 1995 348 355
26. T. Kaasa, J. Loomis, K. Gillis The Edmonton Functional Assessment Tool preliminary development and evaluation for use in palliative care J Pain Symptom Manage 13 1997 10 19
27. M.M. Oken, R.H. Creech, D.C. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1993 649 655
28. A. Heidenreich, A. Elert, R. Hofmann Ibandronate in the treatment of prostate cancer associated painful osseous metastases Prostate Cancer Prostatic Dis 5 2002 231 235
29. A. Heidenreich, C. Ohlmann, P. Olbert High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcemia due to metastatic urologic cancer [abstract 897] Eur J Cancer 1 suppl 5 2003 S270
30. J.-J. Body, I.J. Diel, R. Bell Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer Pain 111 2004 306 312
31. I. Elomaa, T. Kylmala, T. Tammela Effect of oral clodronate on bone pain - A controlled study in patients with metastatic prostate cancer Int Urol Nephrol 24 1992 159 166
32. R. Lahtinen, M. Laasko, I. Palva Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma Lancet 340 1992 1049 1052
33. N. O'Rourke, E. McCloskey, F. Houghton Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases J Clin Oncol 13 1995 929 934
34. G.N. Hortobagyi, R.L. Theriault, L. Porter Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases N Engl J Med 335 1996 1785 1791
35. A. Lipton, R.L. Theriault, G.N. Hortobagyi Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases long-term follow-up of two randomized, placebo-controlled trials Cancer 88 2000 1082 1090
36. G.N. Hortobagyi, R.L. Theriault, A. Lipton Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate J Clin Oncol 16 1998 2038 2044
37. R.L. Theriault, A. Lipton, G.N. Hortobagyi Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions a randomized, placebo-controlled trial J Clin Oncol 17 1999 846 854
38. E.J. Small, M.R. Smith, J.J. Seaman Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer J Clin Oncol 21 2003 4277 4284
39. L.S. Rosen, D. Gordon, M. Kaminski Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
40. B. Kristensen, B. Ejlertsen, M. Groenvold Oral clodronate in breast cancer patients with bone metastases a randomized study J Intern Med 246 1999 67 74